Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00894634
First received: May 5, 2009
Last updated: February 21, 2013
Last verified: February 2013
  Purpose

The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age dosing guidelines. Once characterized, the PK data will be pooled with adult PK data from other studies and analyzed under a separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to <12 yrs and adolescents aged 12 to <18 yrs.


Condition Intervention
Allergic Reactions
Drug: Brompheniramine maleate

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-Dose, Open-Label, Pharmacokinetic Study of Brompheniramine Maleate Liquid in Children and Adolescents

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Log transformed values of AUCL and Cmax [ Time Frame: 72 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: March 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Brompheniramine maleate
Brompheniramine maleate oral solution 1 mg/5 mL, single dose
Drug: Brompheniramine maleate

  Eligibility

Ages Eligible for Study:   2 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or females between 2 to less than 18 yrs of age with a minimum weight of 24 pounds and within the 5th and 95th percentiles in height and weight, and BMI based on age and gender
  2. Symptomatic or asymptomatic children/adolescents as follows:

    • A prior diagnosis of allergic rhinitis and either symptomatic or asymptomatic at the time of entry in the study; or * Symptoms of an acute URI; or
    • No symptoms of an acute URI, but at risk for developing an acute URI as evidenced by the following frequency, crowding, and exposure criteria:

      • Frequency: a history of frequent URIs defined as greater than 6 infections/yr for children aged 2 to less than 6 yrs and as greater than 4 infections per year for adolescents aged 6 to less than 18 yrs;
      • Crowding: living in a home with greater than 4 persons, or sleeping in the same bedroom with greater than 3 persons;
      • Exposure: the presence of another family member in the household who is ill with a URI, or a child in the family that is attending preschool, or attending school with greater than 6 children in the class;
  3. Except for allergic rhinitis or a URI, children/adolescents are in normal physical health (i.e., no clinically significant systemic disease) as judged by the Investigator upon physical examination of the subject;
  4. Subjects do not require concomitant medication except for low-dose inhaled glucocorticoids for allergic rhinitis or mild concomitant asthma, if dose is stabilized before entry in the study (i.e., dose is not changed for one month prior to or during the study), and inhaled short-acting beta-2 adrenergic agonists for concomitant asthma, as needed;
  5. Post menarchal females must be using a reliable method of contraception (i.e., oral, transdermal, injectable or implanted contraceptives, IUD, cervical cap, diaphragm, condom, abstinence, or surgical sterility).

Exclusion Criteria:

  1. The child/adolescent weighs less than 24 pounds or is below the 5th or above the 95th percentiles in physical growth characteristics (i.e., height and weight), and BMI based on age and gender;
  2. Inability to swallow the medication;
  3. Eaten within 2 hours prior to dosing;
  4. A known hypersensitivity to BROM, any other antihistamine, or EMLA cream;
  5. Systolic and/or diastolic blood pressure at or above the 95th percentile based on gender, and age and height percentiles. (Note: If a subject with no history of hypertension has a blood pressure reading at or above the 95th percentile, the subject will be allowed to rest for 15 minutes and the blood pressure measurement repeated. Up to 3 consecutive measurements at approximately 5 min intervals will be allowed. Subjects who continue to have systolic and/or diastolic blood pressure readings at or above the 95th percentile will be excluded from the study);
  6. History of melena or any hepatic, renal, endocrine (e.g., diabetes, thyroid disorder), cardiac, neurological, psychiatric, gastrointestinal, hematological or metabolic disorder deemed to be clinically significant by the Investigator;
  7. Any serious medical condition or medical history felt by the Investigator to place them at increased risk;
  8. The child is diagnosed with anemia or has a red blood cell count or hemoglobin level outside of normal range as evidenced by baseline hematology assessment;
  9. Asthma symptoms at the time of entry in the study or requires medication other than allowed under Inclusion Criterion d;
  10. Failure to comply with appropriate washout periods for any H-1 receptor antagonist treatment before and during the study, i.e., no use within 7 days of entering the study or at any time during the study, and no use of astemizole within the preceding 3 calendar months;
  11. Other than described in Exclusion Criterion i, use of any medication 72 hours prior to dosing;
  12. A history of drug, alcohol, or tobacco abuse (older children and adolescents), a history of Hepatitis B, a previous positive test for Hepatitis B surface antigen, or a previous positive Hepatitis C antibody;
  13. A history of HIV infection or previous demonstration of HIV antibodies;
  14. Female subjects who have experienced menarche and have a positive urine pregnancy test;
  15. Parent/guardian/subject judged by the Investigator to be unable or unwilling to comply with the requirements of the protocol;
  16. Have taken an investigational drug within 30 days prior to entering the study or have already participated in the trial;
  17. Relative of the Sponsor, Investigator, or any personnel of the study site who are directly involved with the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00894634

Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

Responsible Party: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier: NCT00894634     History of Changes
Other Study ID Numbers: BF-08-06
Study First Received: May 5, 2009
Last Updated: February 21, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hypersensitivity
Immune System Diseases
Brompheniramine
Maleic acid
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Anti-Allergic Agents
Therapeutic Uses
Enzyme Inhibitors

ClinicalTrials.gov processed this record on April 17, 2014